| Literature DB >> 30916125 |
Marcos Antonio Cantero1, Rui Manuel Siqueira Almeida2, Priscila Neder Morato3, Valfredo de Almeida Santos-Junior3, Carolina Soares Moura3, Jaime Amaya-Farfan3, João Luis Fonseca1, Pablo Christiano Barboza Lollo1.
Abstract
OBJETIVE: Coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB) improved symptoms and increased survival and quality of life in patients with coronary artery disease. However, it should be the main cause of a complex organic systemic inflammatory response that greatly contributes to several postoperative adverse effects.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30916125 PMCID: PMC6436780 DOI: 10.21470/1678-9741-2018-0231
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
General characteristics of the patients' groups.
| Variable | Uncomplicated evolution (n = 31) | Complicated evolution (n = 15) | Test | |
|---|---|---|---|---|
| Age (years)[ | 59.7±9.4 | 66.3±10 | 0.002 | Student's t-test |
| BSA (m2)[ | 1.81±0.17 | 1.71±0.16 | 0.06 | Student's t-test |
| Weight (kg)[ | 74 (65.5-80) | 65 (60-73.5) | 0.005 | Mann-Whitney |
| Female gender[ | 8 (25.8%) | 6 (40%) | 0.13 | Chi-squared |
| Ejection fraction (VF) | 58±1.3 | 56±1.2 | 0.25 | Mann-Whitney |
Values A1:E18 mean ± standard deviation;
median values and interquartile range;
absolute value (percentages)
BSA=body surface area; VF=ventricular fibrillation
Preoperative variables of patients.
| Variable | Uncomplicated evolution (n=31) | Complicated evolution (n=15) | Test | |
|---|---|---|---|---|
| EuroSCORE[ | 3 (3-5) | 6 (5-8) | <0.001 | Mann-Whitney |
| IAB[ | 3 (6.1%) | 4 (10.5%) | 0.71 | Fisher's test |
| Inotropic and/or vasopressor drugs[ | 1 (3.0%) | 3 (20%) | 0.44 | Fisher's test |
| Nitroglycerin[ | 4 (13%) | 2 (12.5%) | 0.92 | Fisher's test |
| Intraoperative | ||||
| Surgery duration | 280 (240-340) | 312 (245-374) | 0.24 | Mann-Whitney |
| Anesthesia duration | 390 (320-430) | 400 (334-480) | 0.38 | Mann-Whitney |
| CPB time (min)[ | 95 (75-118) | 90 (69-140) | 0.77 | Mann-Whitney |
Median values and interquartile range;
absolute value (percentages)
CPB=cardiopulmonary bypass; IAB=intra-aortic balloon
Comparison between postoperative data of patients who underwent CABG with CPB with uncomplicated and complicated evolutions.
| Variable | Uncomplicated evolution (n=31) | Complicated evolution (n=15) | |
|---|---|---|---|
| Duration of ICU stay (days)[ | 2 (2-4) | 8 (7-21) | <0.001 |
| In-hospital length of stay (days)[ | 7 (6-13) | 21 (14-28) | <0.001 |
| Prolonged intubation[ | 18 (41%) | 11 (75%) | <0.001 |
| Renal complications[ | 1 (3%) | 8 (51%) | <0.001 |
| Neurological complications[ | 0 (0%) | 4 (26%) | <0.001 |
| Infectious complications[ | 9 (29%) | 11 (73%) | <0.001 |
| Low cardiac output[ | 3 (9.6%) | 13 (86.6%) | <0.001 |
| Arrhythmias[ | 2 (6.4%) | 9 (60%) | <0.001 |
Values in median and interquartile range;
Absolute value (percentage)
CABG=coronary artery bypass grafting; CPB=cardiopulmonary bypass; ICU=intensive care unit
Fig. 1EuroSCORE receiver operating characteristic (ROC) curves to predict complications.
Fig. 2Lactate receiver operating characteristic (ROC) curves to predict complications.
Fig. 3Atrial heat-shock protein 70 (HSP 70) expressions receiver operating characteristic (ROC) curves to predict complications.
Fig. 4Serum heat-shock protein 70 (HSP 70) receiver operating characteristic (ROC) curves to predict complications.
Fig. 5Serum and atrial heat-shock protein 70 (HSP 70) receiver operating characteristic (ROC) curves to predict complications.
Statistical analysis of the markers studied.
| Variable | Univariate regression (95% CI) | Multivariate regression (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|
| OR | LL | UL | OR | LL | UL | |||
| EuroSCORE | 2.097 | 1.326 | 3.316 | 0.002 | 1.99 | 1.259 | 3.147 | 0.003 |
| Lactate | 1.573 | 0.978 | 2.529 | 0.062 | 1.449 | 0.744 | 2.82 | 0.276 |
| Atrial HSP 70 | 0.787 | 0.666 | 0.929 | 0.005 | 1.146 | 0.71 | 1.85 | 0.577 |
| Serum HSP 70 | 0.71 | 0.501 | 1.004 | 0.053 | 1.25 | 0.704 | 2.219 | 0.446 |
CI=confidence interval; HSP 70=heat-shock protein 70; LL=lower limit; OR=odds ratio; UL=upper limit
Fig. 6Myocardial expression of heat-shock protein 70 (HSP 70) and evolution outcome. C=complicated; NC=non-complicated
Fig. 7Atrial and serum heat-shock protein 70 (HSP 70) expression in the complicated (C) and non-complicated (NC) group. BSA=body surface area
Fig. 8Linear regression between serum and atrial heat-shock protein 70 (HSP) 70 expression.
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| ACT | = Activated coagulation time | ICU | = Intensive care unit | |
| ATP | = Adenosine triphosphate | IR | = Interquartile range | |
| BSA | = Body surface area | LL | = Lower limit | |
| C | = Complicated | mRNA | = Messenger ribonucleic acid | |
| CABG | = Coronary artery bypass grafting | NC | = Non-complicated | |
| CI | = Confidence interval | OR | = Odds ratio | |
| CO2 | = Carbon dioxide | PMSF | = Phenylmethanesulfonyl fluoride | |
| CPB | = Cardiopulmonary bypass | ROC | = Receiver operating characteristic | |
| EDTA | = Ethylenediaminetetraacetic acid | UFGD | = Federal University of Grande Dourados | |
| Hb | = Hemoglobin | UL | = Upper limit | |
| HSP | = Heat-shock proteins | UNICAMP | = University of Campinas | |
| HSP 70 | = Heat-shock protein | VF | = Ventricular fibrillation | |
| IAB | 70 = Intra-aortic balloon | |||
| Authors' roles & responsibilities | |
|---|---|
| MAC | Design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| RMSA | Drafting the work and revising it critically for important intellectual content; final approval of the version to be published |
| PNM | Substantial contributions to the acquisition of data for the work; final approval of the version to be published |
| VASJ | Substantial contributions to the acquisition of data for the work; final approval of the version to be published |
| CSM | Substantial contributions to the acquisition of data for the work; final approval of the version to be published |
| JAF | Substantial contributions to the acquisition of data for the work; final approval of the version to be published |
| JLF | Substantial contributions to the acquisition of data for the work; final approval of the version to be published |
| PCBL | Design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |